Gyros Protein Technologies' Gyrolab Platform Automates Impurity Testing for ADCs and Bispecifics
The Gyrolab automated immunoassay platform from Gyros Protein Technologies addresses reproducibility and throughput challenges in biotherapeutic development for ADCs and bispecifics. Case studies show measurable improvements in assay consistency and efficiency for titer and impurity testing workflows.
The Gyrolab automated immunoassay platform from Gyros Protein Technologies is designed to improve reproducibility and throughput in biotherapeutic development, particularly for antibody-drug conjugates (ADCs) and bispecific antibodies. Automation eliminates manual steps that introduce inconsistency across runs, operators, and laboratories, while maintaining data integrity.
The biotherapeutic landscape has evolved, with monoclonal antibodies remaining a cornerstone alongside the growing importance of ADCs and bispecifics, adding complexity to analytical teams. Reliable assay performance depends on reproducibility and throughput, placing pressure on workflows where manual steps are a persistent source of variability.
The platform addresses these challenges by reducing hands-on time without compromising data quality, enabling teams to meet tight development timelines. Case studies from biotherapeutic analytical development workflows focusing on titer and process impurity testing demonstrate measurable improvements in assay consistency and run efficiency.